...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: We made it in Endpts news!

Great to see an Endpoints News article. Though, I wish it would have mentioned the incredible ~50%RRR seen in those with CKD as well as in those on SGLT2 or DPP4 inhibitors.

Share
New Message
Please login to post a reply